Free
Meeting Abstracts  |   October 1995
Prolonged Alleviation of Tactile Allodynia by Intravenous Lidocaine in Neuropathic Rats
Author Notes
  • (Chaplan) Assistant Clinical Professor, Anesthesiology Research Laboratory, University of California, San Diego, La Jolla, California.
  • (Bach) Associate Professor, Department of Neurology F, Aarhus University Hospital, Aarhus C, Denmark.
  • (Shafer) Associate Professor, Anesthesiology Service, Veteran's Administration Medical Center, Stanford University School of Medicine, Palo Alto, California.
  • (Yaksh) Professor, Anesthesiology Research Laboratory, University of California, San Diego, La Jolla, California.
  • Received from the Anesthesiology Research Laboratory, University of California, San Diego, La Jolla, California. Submitted for publication June 20, 1994. Accepted for publication May 19, 1995. Supported by National Institutes of Health grant T32NS07329 and the Reflex Sympathetic Dystrophy Association (S.R.C.), the Michaelsen Foundation (F.W.B.), and National Institutes of Health grant DA02110 (T.L.Y.). Presented at the annual meeting of the American Society of Anesthesiologists, Washington, D.C., October 12, 1993.
  • Address reprint requests to Dr. Chaplan: Department of Anesthesiology 0818, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0818.
Article Information
Meeting Abstracts   |   October 1995
Prolonged Alleviation of Tactile Allodynia by Intravenous Lidocaine in Neuropathic Rats
Anesthesiology 10 1995, Vol.83, 775-785.. doi:
Anesthesiology 10 1995, Vol.83, 775-785.. doi:
Methods: Rats underwent ligation of the left fifth and sixth lumbar spinal nerves. The 50% thresholds (g) for left hind paw withdrawal of awake rats to von Frey hairs were documented before, during, and after intravenous administration of lidocaine at programmed/documented pseudo-steady-state plasma concentrations, and correlated with measured plasma concentrations. Responses to lidocaine application intrathecally and regionally to the injured nerves were also recorded.
Results: In rats with tactile allodynia, intravenous lidocaine yielded 66 plus/minus 11% of the maximal possible effect on thresholds (100% = normal threshold), versus -1.3 plus/minus 2.7% for saline infusion. Twenty-one days after lidocaine infusion, 30-40% of the maximal possible effect persisted. Threshold increases depended on plasma concentration, rather than quantity of drug administered: rats receiving 15 mg/kg with higher plasma concentrations (1.2 plus/minus 0.1 micro gram/ml) showed significant allodynia suppression throughout 7 days of follow-up, whereas rats receiving 15 mg/kg at a slower rate with lower plasma concentrations (0.6 plus/minus 0.1 micro gram/ml) did not. The EC sub 50 for acute allodynia suppression was 0.75 micro gram/ml. No such allodynia suppression was seen after intrathecal or regional administration of lidocaine despite transient neural blockade.
Conclusions: Intravenous, but not intrathecal or regionally applied, lidocaine produces dose-dependent suppression of allodynia associated with nerve injury. The effects far outlast plasma concentrations of lidocaine. The mechanism of these prolonged effects is unknown.
Key words: Anesthetics, local: lidocaine; nerve. Injury: peripheral neuropathy; rat; von Frey hairs. Pain, allodynia: mechanical; tactile. Pain, hyperalgesia: mechanical; tactile.
A number of carefully executed clinical studies have shown that systemically administered local anesthetics may have analgesic properties specific to pain states resulting from damage to nerve tissue. [1-7] Analgesia in such neuropathic pain states is attained in the absence of motor or sensory conduction blockade, and at doses without toxic effects. Because neuropathic pain is otherwise difficult to treat and is typically refractory to conventional analgesic agents, these studies have generated considerable interest.
Patients with painful diabetic neuropathy have been shown to benefit with reduced pain scores for several days from the intravenous administration of lidocaine, without alteration in thermal thresholds. [8,4] Patients with pain due to peripheral nerve injury likewise reported decreases in spontaneous pain, albeit of short duration, after receiving intravenous lidocaine. [6] Orally administered available congeners of lidocaine also may be effective, as demonstrated by the analgesic effects of mexiletine in painful diabetic neuropathy [3] and peripheral nerve injury, [1] and tocainide in trigeminal neuralgia. [9] 
After peripheral nerve injury, humans may report both thermal hyperalgesia and tactile allodynia (i.e., pain evoked by light touch or brushing of the skin). Importantly, human psychophysical studies have documented that the predominant evoked pain complaint in peripheral nerve injury sufferers is allodynia. [10,11] Kim and Chung [12] have reported that after ligation of the L5 and L6 spinal nerves in the rat, reliable, long-lasting allodynia develops. In particular, animals so prepared display readily quantifiable paw withdrawal reactions to light mechanical stimuli, comparable in character to the clinical syndrome of tactile allodynia evoked by light touch. We employed this model to study the efficacy and site of action of systemically administered lidocaine in the neuropathic state.
Materials and Methods
All procedures followed protocols approved by the Institutional Animal Use and Care Committee of the University of California, San Diego. Male Harlan Sprague-Dawley rats (weighing 100-200 g) were maintained in a standard facility with a 12-h day (0600-1800) and 12-h night cycle. Water and food pellets were supplied ad libitum. After surgery, rats were housed two or three to a cage with corncob bedding. All surgeries were performed on separate occasions, allowing a minimum of 5 days between procedures for adequate recovery, except as specified later in the case of regional nerve catheter placement at the time of nerve ligation.
Neuropathy
Rats were anesthetized with halothane, 1-3%, in a 34% oxygen/air mixture. The left fifth and sixth lumbar spinal nerves were exposed via a dorsal midline incision and ligated tightly with 6-0 silk suture according to the method described by Kim and Chung. [12] Rats were studied between 5 and 60 days after nerve ligation.
Intrathecal Catheters
Intrathecal PE-10 catheters were implanted under halothane/oxygen anesthesia. [13] The catheters were 9 cm in intrathecal length and terminated near the lumbar enlargement. A rostral 3-cm extension of catheter was tunneled under the skin and externalized between the ears for injection. Rats with neurologic deficits were not used. Catheters were flushed with 10 micro liter preservative-free physiologic saline after insertion and after use for drug delivery.
Intravascular Access
Catheters made from PE-50 tubing were inserted into an external jugular vein under halothane/oxygen anesthesia. Similar catheters with the addition of a small bouton 1 cm from the intravascular tip, for suture retention, were inserted into a carotid artery, taking care to spare the adjacent vagus nerve. All catheters were tunneled subcutaneously to emerge at the base of the neck, flushed before and after each use with heparinized saline (10 units/ml), and capped when not in use.
Indwelling Nerve Blockade Catheters
To allow drug delivery at the nerve injury site in the six rats described later, catheters were fashioned from PE-10 gently bent into a U shape and fused to a PE-50 extension, as previously described. [14] During creation of the nerve ligation, the PE-10 loop was tied down to the newly lesioned nerve bundle, with the catheter lumen directed proximally toward the dorsal root ganglion. Catheters were externalized through the wound closure to the subcutaneous level, secured to the fascia, then tunneled subcutaneously to exit at the neck. These catheters were periodically flushed with sterile normal saline to ensure patency.
Infusion Method
A computer program (Stanpump) designed to rapidly achieve and maintain constant plasma drug concentrations (pseudo-steady-state concentrations) was used to drive a syringe infusion pump (Harvard Apparatus 22, South Natick, MA). A modification of Rowland's kinetics set [15] using experimentally derived rat parameters (Chaplan, Bach, Shafer, and Yaksh: unpublished data) enabled prediction of plasma concentrations and stable maintenance of pseudo-steady-state concentrations in plasma (Figure 2).
Figure 2. Two groups of rats underwent identical intravenous lidocaine infusion protocols, in which a pseudo-steady-state level was sustained over 40 min. One group, consisting of six neuropathic animals, had repeated paw withdrawal threshold testing. The second group consisted of four normal rats equipped with arterial catheters for blood sampling. Samples were drawn at all time points corresponding to paw testing in the neuropathic group; mean plasma lidocaine concentration overall was 1.34 plus/minus 0.07 micro gram/ml. Significant increases in paw withdrawal thresholds were seen beginning 30 min after attaining targeted plasma lidocaine levels. (P < 0.001, repeated measures analysis of variance with mean squares contrasts). X-axis: time; left y-axis: paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE; right y-axis: plasma lidocaine levels, micro gram/ml plus/minus SE.
Figure 2. Two groups of rats underwent identical intravenous lidocaine infusion protocols, in which a pseudo-steady-state level was sustained over 40 min. One group, consisting of six neuropathic animals, had repeated paw withdrawal threshold testing. The second group consisted of four normal rats equipped with arterial catheters for blood sampling. Samples were drawn at all time points corresponding to paw testing in the neuropathic group; mean plasma lidocaine concentration overall was 1.34 plus/minus 0.07 micro gram/ml. Significant increases in paw withdrawal thresholds were seen beginning 30 min after attaining targeted plasma lidocaine levels. (P < 0.001, repeated measures analysis of variance with mean squares contrasts). X-axis: time; left y-axis: paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE; right y-axis: plasma lidocaine levels, micro gram/ml plus/minus SE.
Figure 2. Two groups of rats underwent identical intravenous lidocaine infusion protocols, in which a pseudo-steady-state level was sustained over 40 min. One group, consisting of six neuropathic animals, had repeated paw withdrawal threshold testing. The second group consisted of four normal rats equipped with arterial catheters for blood sampling. Samples were drawn at all time points corresponding to paw testing in the neuropathic group; mean plasma lidocaine concentration overall was 1.34 plus/minus 0.07 micro gram/ml. Significant increases in paw withdrawal thresholds were seen beginning 30 min after attaining targeted plasma lidocaine levels. (P < 0.001, repeated measures analysis of variance with mean squares contrasts). X-axis: time; left y-axis: paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE; right y-axis: plasma lidocaine levels, micro gram/ml plus/minus SE.
×
Mechanical Thresholds
Rats were placed in a plastic cage with an open wire mesh bottom and allowed to accommodate for approximately 15 min. A series of eight von Frey-type filaments with exponentially incremental stiffness (0.41, 0.70, 1.20, 2.00, 3.63, 5.50, 8.50, and 15.10 g; Stoelting, Wood Dale, IL) was employed to determine the 50% threshold for paw withdrawal to light mechanical stimuli, using a previously described up-and-down paradigm summarized later. [16] Only the left hind paw was tested, because (1) the ability or willingness of the rat to bear weight on the left hind paw may have altered any results of testing applied to the "normal" right hind paw; and (2) other investigators have shown alterations in both left and right spinal cord dorsal horn neurochemical environments after unilateral lesions, calling into question the validity of the contralateral paw as a control. [17-20] Instead, parallel groups of rats were used as controls. In brief, von Frey hairs were gently applied to the mid-plantar paw, with sufficient force to cause slight filament buckling. A positive response was noted whenever the paw was sharply withdrawn, and a negative response was recorded if no paw withdrawal occurred. The presentation of filaments was always in sequential order of stimulus intensity. The direction of presentation, however, (ascending or descending intensity) was reversed each time the threshold of response was crossed, so as to first locate the approximate minimum stimulus necessary for paw withdrawal, and then refine the measurement by oscillating further around the threshold. Paw withdrawal thresholds were calculated by noting the stimulus level at which the first change in response occurred, indicating preliminary identification of the threshold range, collecting four additional responses, and mathematically interpolating the 50% response threshold using the method described by Dixon. [21] In cases where response thresholds fell outside the range of detection, i.e., continuous positive or negative responses were observed to the limit of the range of stimuli, values of 0.25 g (maximally neuropathic) or 15.00 g (normal, based on our previous observations) were respectively assigned. Because the results thus computed do not yield a mathematical continuum (not all possible values can be generated), nonparametric statistical methods were used to compare such "raw" thresholds. For some comparisons, raw thresholds were converted to percent of maximum possible effect (%MPE), designating pretreatment paw withdrawal thresholds (baseline values) as 0% effect, and assigning a cutoff value of 100% effect to thresholds greater or equal to 15 g: therefore, %MPE values near 100 indicate normal mechanical thresholds (i.e., at or near 15 g), whereas values near 0 indicate allodynia. The following equation was used to compute %MPE: Equation 1.
Experimental Design: Effect of Lidocaine on Normal Rats
Normal (i.e., nonlesioned) rats prepared with both intrathecal and intravenous catheters (N = 12), were divided into two groups. The first group (N = 6) received an infusion of lidocaine designed to rapidly achieve a plasma concentration of 2.5 micro gram/ml, and maintain that plasma concentration for 30 min. The second group (N = 6) received the same volume of infusate containing only saline. Paw withdrawal thresholds were measured after 30 min of infusion and compared. These animals were not further used in the present studies.
Acute/Long-term Effect in Rats with Neuropathy: Lidocaine Versus Saline
Four weeks after nerve ligation, rats were assigned to groups for either lidocaine or saline infusion, using a random number table. The investigator assessing mechanical thresholds was blinded to the treatment. Lidocaine (Abbott, Abbott Park, IL, 2%, diluted in normal saline to 5 mg/ml; N = 6), or an identical volume of saline (N = 5), was continuously infused intravenously at an incremental rate to an endpoint of complete allodynia suppression, or a maximum infusion volume corresponding to a lidocaine dose of 30 mg/kg, over a period of approximately 60 min. At the conclusion of this acute phase of the experiment, intravascular catheters were trimmed and capped, and rats were returned to the animal facility. Testing was performed daily on days 1-14, and then on days 17, 19, and 21.
Acute Time Effect
To examine the relationship between plasma concentration and time, neuropathic rats with intrajugular catheters (N = 6) received lidocaine at rates calculated to maintain a pseudo-steady-state plasma concentration (plateau) close to 2 micro gram/ml, to a cumulative dose of 15 mg/kg. Paw withdrawal thresholds were tested 5, 10, 20, 30, and 40 min into the plateau phase of the infusion, after completion of the approximately 9-min rapid bolus infusion phase required to achieve the targeted concentration. A parallel group of noninjured rats with both intrajugular and intraarterial catheters received identical infusions (N = 4), and arterial blood samples were drawn at all time points corresponding to threshold measurements in the neuropathic rats.
High Versus Low Plasma Concentration Lidocaine
To examine the importance of plasma concentration achieved versus total dose of lidocaine administered, rats with both intrajugular and intraarterial catheters were randomly assigned to receive a dose of lidocaine in such a fashion as to achieve a plasma target concentration previously found to suppress mechanical allodynia as above (high target: group A), or the same total dose in mg/kg, but delivered in such a way that plasma concentrations remained at approximately half the demonstrated effective target concentration (low target: group B). Intravenous infusions of lidocaine designed to achieve and maintain plasma concentrations in the vicinity of 2 micro gram/ml were administered to group A to a cumulative dose of 15 mg/kg (n = 11). Group B received an infusion designed to maintain a plateau concentration of half the concentration in group A, administered over 85 min, for a cumulative dose again of 15 mg/kg (n = 9). Paw withdrawal thresholds were tested every 10 min, and arterial blood samples were drawn when allodynia suppression was achieved, or at the end of the infusion. At the conclusion of the experiment, rats were returned to the animal facility, and paw withdrawal thresholds were tested thereafter on posttreatment days 1, 5, and 7 (n = 8, group A, and n = 6, group B).
Effect Site
Spinal Cord. To determine whether lidocaine has an antiallodynic action when directly applied to the spinal cord, a dose of 500 micro gram lidocaine was administered intrathecally in a volume of 10 micro liter, followed by 10 micro liter saline flush (N = 6). This dose was chosen to grossly exceed any cerebrospinal fluid concentration of lidocaine that might be achieved by systemic infusion, and to produce obvious transient motor dysfunction as a marker of effective drug placement. Paw withdrawal thresholds were tested at baseline before dosing (0 min) and at time points beginning when motor function completely returned to normal after lidocaine instillation (30, 45, 60 min). The effects on mechanical thresholds, expressed as %MPE, were compared to baseline values.
Spinal Nerve. To explore the possibility of a site of action at the injured axon, rats prepared as described earlier with indwelling nerve block catheters were dosed with 1 mg lidocaine regionally applied to the nerve ligation site, in a volume of 50 micro liter (20 mg/ml; N = 6). Paw withdrawal thresholds were tested at 5, 10, 15, 30, and 60 min after drug treatment, and compared to pretreatment baseline values.
Lidocaine Assays
Samples were obtained by withdrawing and discarding approximately 0.3 ml of blood from the arterial cannulae, and then withdrawing samples of approximately 0.5 ml volume. These samples were centrifuged and the plasma supernatant was frozen at -20 degrees Celsius until analysis. Lidocaine was extracted from the thawed samples by solid-phase extraction chromatography. [22] 
Gas Chromatography Instrumentation and Chromatographic Conditions
Lidocaine was quantitated by capillary gas chromatography with nitrogen-phosphorus detection. [23] A Hewlett-Packard 5890 II gas chromatograph (Palo Alto, CA) was equipped with a methyl-silicone gum (HP-1) capillary column (25 M x 0.2 mm x 0.33 micro Meter), programmed with injector and detector temperatures of 265 degrees Celsius. Split injections (1.5:1) were performed with a Hewlett-Packard 7673A automatic sampler, and the chromatograms were recorded and analyzed with H-P Chemstation (MSDOS) software. The helium carrier gas flow rate was 0.9 ml/min (32 psi). Hydrogen and air flow rates in the detector were 3 and 120 ml/min, respectively. The oven temperature was programmed at 240 degrees Celsius for 1 min, raised over 1 min to a final temperature of 270 degrees Celsius, and held at 270 degrees Celsius for 4 min. Total run time was 5 min; lidocaine and bupivacaine (used as an internal standard) eluted at 2.4 and 4.0 min, respectively. The absolute limit of detection by this method was 0.05 ng lidocaine/micro liter serum. The interassay and intraassay coefficients of variation were 4.2% and 2.5%, respectively, for serum lidocaine concentrations between 0.1 and 1.0 ng/micro liter.
Statistics
Results are expressed as mean plus/minus SE, or median (95% confidence intervals). Median paw withdrawal thresholds before and after infusion were compared using the Wilcoxon signed-rank test if paired and the Mann-Whitney U test if unpaired. Changes in %MPE, designating pretreatment paw withdrawal thresholds as 0% effect and threshold values of greater or equal to 15 g as 100% effect (see above), were compared using repeated measures analysis of variance. When P values were less than 0.05, we identified significant differences between pairs by contrast calculations (means comparisons). Nonparametric repeated-measures analyses were performed using the Friedman test. Lidocaine blood concentrations were compared using a two-tailed t test.
Results
Effect of Lidocaine in Normal Rats
No effect of intravenous lidocaine infusion was seen in normal rats: no difference was seen between paw thresholds in the lidocaine and saline groups (15 plus/minus 0 g, both groups; data not shown). No differences in behavior were noted between groups during the infusions.
Acute/Long-term Effect: Lidocaine Versus Saline
Rats with neuropathy, infused with lidocaine, showed a clear suppression of allodynia. The median paw withdrawal threshold was 2.18 g (1.69-2.62 g) before infusion (baseline), whereas after infusion thresholds rose significantly to a median of 11.17 g (7.14-14.10; P = 0.028, Wilcoxon signed-rank). These postinfusion values corresponded to a %MPE of 65.8 plus/minus 10.8. The thresholds in rats receiving saline did not change significantly during the same time interval, with a baseline median of 2.20 g (1.08-2.61 g) and a postinfusion median of 1.56 g (0.00-2.58 g; P = 0.89, Wilcoxon signed rank), corresponding to a %MPE of -1.3 plus/minus 2.7. Comparison of treatment effects on mechanical thresholds (%MPE) over the subsequent 21 days revealed a sustained difference between the two groups (Figure 1), which was significantly different by repeated measures analysis of variance at P < 0.0002. No evidence of toxicity was observed in any rats either during the infusion or the follow-up period. Rats appeared well groomed and had smooth coats, were active and alert, without chromodacryorhinorrhea or other overt signs of stress, and did not autotomize. Though not systematically recorded, informal observation suggested that rats with normalized mechanical thresholds after lidocaine also displayed increased weight-bearing on the affected paw, with decreased guarding behaviors.
Figure 1. After a single intravenous lidocaine infusion to complete allodynia suppression or a maximum of 30 mg/kg over approximately 60 min on day 0, neuropathic rats were followed for 3 weeks (N = 6) and simultaneously compared with rats that received saline infusions of equivalent volume using the same paradigm (N = 5). Blinded assessment revealed a highly significant difference between groups, with sustained allodynia suppression in the lidocaine-treated rats, and an absence of spontaneous neuropathy resolution in the saline controls (P = 0.0002, repeated measures analysis of variance). X-axis, day relative to lidocaine infusion; y-axis, paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE.
Figure 1. After a single intravenous lidocaine infusion to complete allodynia suppression or a maximum of 30 mg/kg over approximately 60 min on day 0, neuropathic rats were followed for 3 weeks (N = 6) and simultaneously compared with rats that received saline infusions of equivalent volume using the same paradigm (N = 5). Blinded assessment revealed a highly significant difference between groups, with sustained allodynia suppression in the lidocaine-treated rats, and an absence of spontaneous neuropathy resolution in the saline controls (P = 0.0002, repeated measures analysis of variance). X-axis, day relative to lidocaine infusion; y-axis, paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE.
Figure 1. After a single intravenous lidocaine infusion to complete allodynia suppression or a maximum of 30 mg/kg over approximately 60 min on day 0, neuropathic rats were followed for 3 weeks (N = 6) and simultaneously compared with rats that received saline infusions of equivalent volume using the same paradigm (N = 5). Blinded assessment revealed a highly significant difference between groups, with sustained allodynia suppression in the lidocaine-treated rats, and an absence of spontaneous neuropathy resolution in the saline controls (P = 0.0002, repeated measures analysis of variance). X-axis, day relative to lidocaine infusion; y-axis, paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE.
×
Acute Time Effect
Paw withdrawal was inhibited in a cumulative fashion by the continuous administration of intravenous lidocaine at a pseudo-steady-state plasma concentration (in the parallel group) of 1.34 plus/minus 0.07 micro gram/ml for a period of 40 min. Median paw withdrawal threshold increased gradually during the 40-min infusion period to a final value of 12.68 g (7.07-14.87 g), compared to a baseline value of 1.56 g (1.00-2.80 g). Figure 2shows both the stable plasma concentrations generated by the software-driven infusion and the steady increase in paw thresholds, expressed as %MPE, as a function of time. Although plasma concentrations achieved were slightly lower than the targeted levels, more importantly, concentrations were steady over time and correlated in a linear fashion with targeted values. Repeated measures analysis of variance yielded a P value of < 0.001 for %MPE during lidocaine infusion; using contrasts (means comparison), the 30- and 40-min time points were shown to be the points that significantly differed from baseline.
High Versus Low Plasma Concentration Lidocaine
Rats receiving the higher target concentration of lidocaine (group A) achieved allodynia suppression. The median baseline value for paw withdrawal threshold in this group was 1.56 g (1.19-2.19 g), which was significantly below that recorded at the end of the infusion period, 15.00 g (12.41-15.76 g; P = 0.0033, Wilcoxon signed-rank test). Rats receiving the lower target concentration (group B), receiving the same cumulative dose (15 mg/kg) administered over a longer period (85 min), did not achieve significant allodynia suppression (baseline thresholds of 2.80 g (1.64-3.15 g) versus postinfusion, 3.31 g (2.22-4.39 g; P = 0.067, Wilcoxon signed-rank test). Paw withdrawal thresholds in group A were significantly higher than in group B immediately after infusion (P = 0.002, Mann-Whitney). At the end of the infusion period, blood concentrations in the higher target infusion group (A) were 1.21 micro gram/ml plus/minus 0.09 and in the lower target infusion group (B), 0.61 micro gram/ml plus/minus 0.10 (P = 0.0007, two-tailed t test). Rats in group A continued to show significant allodynia suppression during the 7 days of follow-up (P = 0.0006, Friedman test). No suppression of allodynia appeared during the follow-up period for rats in group B (P = 0.67, Friedman test; Figure 3).
Figure 3. Two groups of neuropathic rats received the same total dose of intravenous lidocaine (15 mg/kg), delivered in one group (A) as a faster infusion achieving a mean plasma lidocaine concentration of 1.2 micro gram/ml (N = 11), and in the other group (B) as a slower infusion achieving a mean concentration of 0.6 micro gram/ml (N = 9). Paw withdrawal thresholds were tested every 10 min, and blood levels were drawn at the achievement of allodynia suppression, or at the end of the infusion. Median paw withdrawal thresholds are shown for pretreatment baseline, immediately post treatment, and posttreatment days 1,5 and 7 (N = 8, group A, and N = 6, group B). Error bars represent interquartile range. Whereas significant threshold increases were achieved after acute infusion in group A (P = 0.0033, Wilcoxon signed-rank test), which persisted at least 7 days (P = 0.0006, Friedman test), threshold changes in group B did not reach significance acutely (P = 0.067, Wilcoxon signed-rank test) and were not significant during follow-up (P = 0.67, Friedman test). X-axis: time points; y-axis: median paw withdrawal thresholds (g).
Figure 3. Two groups of neuropathic rats received the same total dose of intravenous lidocaine (15 mg/kg), delivered in one group (A) as a faster infusion achieving a mean plasma lidocaine concentration of 1.2 micro gram/ml (N = 11), and in the other group (B) as a slower infusion achieving a mean concentration of 0.6 micro gram/ml (N = 9). Paw withdrawal thresholds were tested every 10 min, and blood levels were drawn at the achievement of allodynia suppression, or at the end of the infusion. Median paw withdrawal thresholds are shown for pretreatment baseline, immediately post treatment, and posttreatment days 1,5 and 7 (N = 8, group A, and N = 6, group B). Error bars represent interquartile range. Whereas significant threshold increases were achieved after acute infusion in group A (P = 0.0033, Wilcoxon signed-rank test), which persisted at least 7 days (P = 0.0006, Friedman test), threshold changes in group B did not reach significance acutely (P = 0.067, Wilcoxon signed-rank test) and were not significant during follow-up (P = 0.67, Friedman test). X-axis: time points; y-axis: median paw withdrawal thresholds (g).
Figure 3. Two groups of neuropathic rats received the same total dose of intravenous lidocaine (15 mg/kg), delivered in one group (A) as a faster infusion achieving a mean plasma lidocaine concentration of 1.2 micro gram/ml (N = 11), and in the other group (B) as a slower infusion achieving a mean concentration of 0.6 micro gram/ml (N = 9). Paw withdrawal thresholds were tested every 10 min, and blood levels were drawn at the achievement of allodynia suppression, or at the end of the infusion. Median paw withdrawal thresholds are shown for pretreatment baseline, immediately post treatment, and posttreatment days 1,5 and 7 (N = 8, group A, and N = 6, group B). Error bars represent interquartile range. Whereas significant threshold increases were achieved after acute infusion in group A (P = 0.0033, Wilcoxon signed-rank test), which persisted at least 7 days (P = 0.0006, Friedman test), threshold changes in group B did not reach significance acutely (P = 0.067, Wilcoxon signed-rank test) and were not significant during follow-up (P = 0.67, Friedman test). X-axis: time points; y-axis: median paw withdrawal thresholds (g).
×
Effect Site: Intrathecal and Regional Nerve Application
Rats receiving 500 micro gram of intrathecal lidocaine exhibited transient motor block (flaccidity) of 10-15 min maximum duration affecting the hind quarters but not the forequarters. During this time paw withdrawal could not be assessed. Testing of paw withdrawal thresholds after resolution of motor block (as evidenced by normal stance, gait, and righting reflexes) revealed no differences from baseline at 30 and 60 min; a mean threshold elevation at 45 min representing a 13.7 plus/minus 4% MPE was statistically significant (P = 0.02, repeated-measures analysis of variance with contrasts). Application of lidocaine directly to the site of nerve injury by means of indwelling catheters caused conduction blockade of a transient nature, manifested as transient paw flaccidity with decreased withdrawal responses to pinch as well as to light tactile stimuli. After resolution of acute blockade, no further effect on allodynia was detectable with regional administration. Figure 4shows the mechanical thresholds after both intrathecal and regional lidocaine administration.
Figure 4. (A) Lidocaine 500 micro gram was administered intrathecally to six neuropathic rats (10 micro liter of 5% lidocaine in saline). This dose was chosen to exceed hypothetical cerebrospinal fluid concentrations of lidocaine achieved with intravenous infusion. All rats developed complete, transient lower body flaccidity (effective spinal anesthesia). After resolution of motor weakness, paw withdrawal thresholds were compared to predrug values. The significant albeit small effect at 45 min (P = 0.02, repeated measures analysis of variance with means comparisons contrast tests) was not present at 30 min and was absent by 60 min. (B) Catheters were implanted at the site of nerve ligation with orifices directed centrally (6 rats). After full recovery and documentation of withdrawal thresholds to von Frey hairs, catheters were injected with 50 micro liter of 2% lidocaine (1 mg = approximately 4 mg/kg in a 250 g rat). Transient analgesia to paw pinch and partial paw weakness were seen in all six rats (data not shown), demonstrating satisfactory delivery to the ligation site. By 15 min after treatment, von Frey hair thresholds were again indistinguishable from pretreatment (P = 0.97, repeated measures analysis of variance, means comparisons contrasts). X-axes: time; y-axes: paw withdrawal thresholds expressed as percent of maximum possible effect.
Figure 4. (A) Lidocaine 500 micro gram was administered intrathecally to six neuropathic rats (10 micro liter of 5% lidocaine in saline). This dose was chosen to exceed hypothetical cerebrospinal fluid concentrations of lidocaine achieved with intravenous infusion. All rats developed complete, transient lower body flaccidity (effective spinal anesthesia). After resolution of motor weakness, paw withdrawal thresholds were compared to predrug values. The significant albeit small effect at 45 min (P = 0.02, repeated measures analysis of variance with means comparisons contrast tests) was not present at 30 min and was absent by 60 min. (B) Catheters were implanted at the site of nerve ligation with orifices directed centrally (6 rats). After full recovery and documentation of withdrawal thresholds to von Frey hairs, catheters were injected with 50 micro liter of 2% lidocaine (1 mg = approximately 4 mg/kg in a 250 g rat). Transient analgesia to paw pinch and partial paw weakness were seen in all six rats (data not shown), demonstrating satisfactory delivery to the ligation site. By 15 min after treatment, von Frey hair thresholds were again indistinguishable from pretreatment (P = 0.97, repeated measures analysis of variance, means comparisons contrasts). X-axes: time; y-axes: paw withdrawal thresholds expressed as percent of maximum possible effect.
Figure 4. (A) Lidocaine 500 micro gram was administered intrathecally to six neuropathic rats (10 micro liter of 5% lidocaine in saline). This dose was chosen to exceed hypothetical cerebrospinal fluid concentrations of lidocaine achieved with intravenous infusion. All rats developed complete, transient lower body flaccidity (effective spinal anesthesia). After resolution of motor weakness, paw withdrawal thresholds were compared to predrug values. The significant albeit small effect at 45 min (P = 0.02, repeated measures analysis of variance with means comparisons contrast tests) was not present at 30 min and was absent by 60 min. (B) Catheters were implanted at the site of nerve ligation with orifices directed centrally (6 rats). After full recovery and documentation of withdrawal thresholds to von Frey hairs, catheters were injected with 50 micro liter of 2% lidocaine (1 mg = approximately 4 mg/kg in a 250 g rat). Transient analgesia to paw pinch and partial paw weakness were seen in all six rats (data not shown), demonstrating satisfactory delivery to the ligation site. By 15 min after treatment, von Frey hair thresholds were again indistinguishable from pretreatment (P = 0.97, repeated measures analysis of variance, means comparisons contrasts). X-axes: time; y-axes: paw withdrawal thresholds expressed as percent of maximum possible effect.
×
Dose-Response Analysis
After determination of the delayed onset of allodynia blockade as demonstrated in Figure 2, all plasma lidocaine concentrations obtained after at least 30 min of intravenous lidocaine administration were correlated with simultaneously determined paw withdrawal thresholds. This analysis resulted in a sigmoidal dose-response curve. Logit analysis (log[y/(100 - y]) was performed to linearize the sigmoidal curve (Figure 5). The plasma lidocaine concentration corresponding to 50% suppression of allodynia was calculated as 0.75 micro gram/ml using this analysis.
Figure 5. Intravenous infusion of lidocaine, using a software-driven syringe pump, produced pseudo-steady-state plasma lidocaine levels during which paw withdrawal thresholds were measured. Arterial lidocaine levels drawn greater or equal to 30 min after start of infusion correlated with the degree of suppression of allodynia. There were no signs of toxicity at the levels illustrated. Untransformed data (inset): x-axis = log measured lidocaine concentration, y-axis = percent of maximum possible effect. In the surrounding figure, percent of maximum possible effect has been given logit transformation (y' = log [y/(100 - y)]) for linear depiction of the sigmoid dose-response curve. R = 0.76, P < 0.01, linear regression. X-axis: log measured plasma lidocaine concentration; y-axis, logit transformation of percent of maximum possible effect as above.
Figure 5. Intravenous infusion of lidocaine, using a software-driven syringe pump, produced pseudo-steady-state plasma lidocaine levels during which paw withdrawal thresholds were measured. Arterial lidocaine levels drawn greater or equal to 30 min after start of infusion correlated with the degree of suppression of allodynia. There were no signs of toxicity at the levels illustrated. Untransformed data (inset): x-axis = log measured lidocaine concentration, y-axis = percent of maximum possible effect. In the surrounding figure, percent of maximum possible effect has been given logit transformation (y' = log [y/(100 - y)]) for linear depiction of the sigmoid dose-response curve. R = 0.76, P < 0.01, linear regression. X-axis: log measured plasma lidocaine concentration; y-axis, logit transformation of percent of maximum possible effect as above.
Figure 5. Intravenous infusion of lidocaine, using a software-driven syringe pump, produced pseudo-steady-state plasma lidocaine levels during which paw withdrawal thresholds were measured. Arterial lidocaine levels drawn greater or equal to 30 min after start of infusion correlated with the degree of suppression of allodynia. There were no signs of toxicity at the levels illustrated. Untransformed data (inset): x-axis = log measured lidocaine concentration, y-axis = percent of maximum possible effect. In the surrounding figure, percent of maximum possible effect has been given logit transformation (y' = log [y/(100 - y)]) for linear depiction of the sigmoid dose-response curve. R = 0.76, P < 0.01, linear regression. X-axis: log measured plasma lidocaine concentration; y-axis, logit transformation of percent of maximum possible effect as above.
×
Discussion
The major findings of this study are that (1) intravenously administered lidocaine produces plasma-concentration-dependent reversal of tactile allodynia associated with nerve injury; (2) the reversal occurs at a dose that has no detectable effect on normal motor function; (3) the effects are unexpectedly persistent; and (4) the effects achieved by systemic administration are not reproduced by application directly to the spinal cord or the affected peripheral nerve. In this model, lidocaine did not suppress allodynia immediately: there was an approximate 30-min latency during pseudo-steady-state drug administration before significant effects were seen. Our results exclude the possibility that the delay in onset relates to slow distribution to either the cerebrospinal compartment or the site of nerve lesion. A plasma concentration-response relationship was evident for allodynia suppression as assessed immediately after infusion. A similar relationship emerged for long-term suppression of allodynia as well, because the group of rats with mean plasma concentrations of 1.2 micro gram/ml immediately after infusion continued to have persistently increased mechanical thresholds, whereas the group with mean concentrations of 0.6 micro gram/ml did not.
Mechanism of Action
Widespread Consequences of Peripheral Nerve Injury. After injury to a peripheral nerve, substantial functional alterations occur in both the peripheral and central nervous systems. Sustained, low-level ectopic spontaneous activity originates at the site of neuroma formation in large peripheral axons [2] as well as in dorsal root ganglion cells. [24] While the basis of this spontaneous electrical activity is not known, abnormalities of axonal sodium channel distribution have been described in association with demyelination after peripheral nerve injury [25,26] that may lead to spontaneous fiber activity. [27] In addition, the appearance after nerve injury of an unusual type of "modified rapidly adapting" cutaneous mechanoreceptor has been identified, which although not spontaneously active, shows abnormally prolonged, weak, irregular discharges to light mechanical stimuli. [28] Prominent increases are also seen in the evoked activity of dorsal horn neurons, which project supraspinally. [29,30] Similar sustained central activity is demonstrable after the application of N-methyl-D-aspartate type glutamate agonists, [31] which leads not only to electrophysiologic facilitation of neuronal responses but also to the behavioral manifestation of tactile allodynia. [32] Thus, continued afferent pathway activity is linked to behavioral states wherein modest stimuli may evoke pronounced responses. These changes in electrical activity are associated with peripheral and central changes including alterations in receptor expression [33,34] second messenger function, [35,36] neurotransmitter production, [37] likely neuronal dropout, [38] and possibly altered balance of inhibitory/excitatory neurotransmitters. [39] The sum total of these mechanisms may provide a scenario whereby nerve injury leads to an anomalous pain state.
Effect of Lidocaine on Neuronal Activity. Owing to its well known properties of conduction blockade, lidocaine has been assayed in afferent systems primarily using electrophysiologic assessments. A number of investigations have examined the effects of lidocaine on evoked or spontaneous neural activity such as described earlier. A systematic examination in patients with painful diabetic neuropathy [8] has suggested a spinal or supraspinal effect site because of suppression of the centrally organized nociceptive flexion response. In addition, considerable evidence from the preclinical literature supports a spinal cord or supraspinal site of action of intravenously administered lidocaine in facilitated pain states. [40-44] Lidocaine, with an octanol: water distribution coefficient of 110 at 36 degrees Celsius, pH 7.4, [45] distributes promptly to central nervous system structures after systemic administration. [46] The effects of a systemically delivered dose appear more potent in central than in peripheral nervous structures. Although peripheral terminals clearly respond to lidocaine, they appear to do so only at a relatively high concentration. A single study has derived in vitro dose-response curves for the suppressant effect of lidocaine on spontaneous activity in acutely injured peripheral terminals. The reported ED50of 5.7 micro gram/ml however, reflects drug in an artificial, protein-free system [47]; a substantially higher plasma concentration would in all likelihood be required for a comparable investigation in vivo, considering that lidocaine is extensively protein-bound in circulation. In whole animals, the ED50of intravenous lidocaine for discharge suppression in neuromata has been reported to be 6 mg/kg, whereas that for the dorsal root ganglion is lower at 1 mg/kg, [48] a dose that also yields suppression of polysynaptic (spinal cord) sural nerve evoked afterdischarges. [44] Dose-related suppression of neurons in Rexed lamina V to high threshold mechanical and noxious thermal stimuli is seen in decerebrate cats (plasma concentration = 3-10 micro gram/ml). [40] Intravenous lidocaine (1-5 mg/kg) suppresses polysynaptic C-fiber evoked flexor responses to mustard oil and noxious heat, without evidence of conduction block at the peripheral terminal. [44] Intravenous lidocaine (3-4 mg/kg) suppresses noxious-evoked activity in wide dynamic range neurons in the rat, and, in addition, selectively suppresses the increased wide dynamic range neuronal activity seen ipsilateral to chronic peripheral nerve injury. [42,43] To date, no studies have specifically examined the effects of systemically administered lidocaine on supraspinal structures or descending pathways in the context of hyperalgesia or increased evoked responses.
Effect Site of Lidocaine. These potent central effects strongly suggest that lidocaine can exert a central action. Although our local spinal delivery work demonstrates that the prolonged effects cannot be accounted for by a simple direct local action of lidocaine, the spinal cord should not be excluded from further consideration based solely on the current results. Our observations, including the delay in onset of the antiallodynic effect of intravenous lidocaine and the need for systemic delivery, raise the possibility, among other hypotheses, that biotransformation of the administered drug may be a prerequisite. Several metabolites with local anesthetic/antiarrhythmic activity, and half-lives as long as or longer than the parent compound, are produced in the liver, including monoethylglycinexylidide and glycinexylidide. [49] It should be noted that the activity of intravenous lidocaine in a dorsal horn recording preparation exceeds that of iontophoresed lidocaine, suggesting that the species active in producing effects at the spinal cord level could in fact be a metabolite. [50] 
We have considered the possibility that lidocaine might be acting via sympathetic nervous system blockade in this model, known to be responsive to sympathectomy. [51,52] The minimal and transient sympatholytic effects of systemically administered lidocaine recently reported in a rabbit mesentery model do not support this hypothesis, [53] although we did not directly test sympathetic activity in this study.
In addition, we cannot exclude a supraspinal effect of lidocaine based on our results. To date, no investigations have addressed this issue. It is open to conjecture whether lidocaine might exert a direct brain effect resulting in analgesia, or influence descending modulatory pathways.
Persistence of the Allodynia Suppression. The persistence of the effect of brief systemic exposure to lidocaine on allodynia behavior in our study was particularly unexpected, and is not readily explainable according to currently understood mechanisms of action of local anesthetics. The plasma half-life of lidocaine is no more than 30 min in the rat, [54] whereas the duration of allodynia suppression was clearly greater than several hundred half-lives. Long-lasting suppression of allodynia was reproduced in two separate experiments and thus was a reliable finding of this investigation. Though controversial, there is precedent in both the clinical and animal literature for prolonged consequences of lidocaine treatment. Controlled clinical trials [8,4,5] as well as anecdotal reports [55,56] have noted persistent effects. In recent work, we observed decreases in thermal hyperalgesia that persisted for 24 h after intravenous lidocaine treatment in the Bennett chronic nerve constriction (rat) model. [57] The present study, however, is the first to show persistent effects of lidocaine treatment of this magnitude and duration in an animal model of neuropathic pain.
Clearance of lidocaine from a tissue site (as in a peripheral nerve block) depends on local tissue blood flow, and may be prolonged. Unexpectedly, however, we found that the effects after delivery into the systemic circulation far outlasted those of regional application. This finding argues against allodynia suppression occurring as an accompaniment to neurotoxicity, because greater local concentrations achieved by direct application of the drug to peripheral nerve and spinal cord had far less effect than exposures to lower concentrations by intravenous administration.
Prolonged effects of several weeks might appear to point to some form of persistence of the drug at an active tissue site. We attempted to address the possibility of a depot drug action by administering an identical total dose in mg/kg to groups of rats using two different plasma concentration profiles, subjecting one group to a shorter infusion with a higher plasma concentration and the second to a longer infusion attaining half the plasma concentration. The observation that persistent allodynia suppression was only seen in the group receiving the higher plasma concentration appears to argue against any hypothesis whereby a depot of accumulated drug might explain persistent drug action.
Reversible sodium channel blockade is the most often described major pharmacologic property of lidocaine. It is possible that the action of lidocaine may be different in excitable tissues after injury, in a way that remains to be elucidated. For example, after injury, the expression of different isoforms of both acetylcholine receptors and sodium channels at the neuromuscular junction [58,59] leads to a distinct pharmacology of the postinjury state. Functionally differing subpopulations of sodium channels have already been well described within the normal dorsal root ganglion. Channels associated with the smaller dorsal root ganglion cells, which likely give rise to small unmyelinated fibers (C-fibers), display the particular characteristic of use-dependent blockade with lidocaine. [60] Although the role of C-fibers per se has been questioned in both the induction and maintenance of tactile allodynia, [61-63] it is speculated that a channel isoform, hypothetically expressed in afferent pathways after neuronal damage, could be subject to exaggerated use-dependent blockade by lidocaine.
We raise the additional hypothesis that lidocaine may be acting at a novel locus, one other than the sodium channel, perhaps by a mechanism of action that leads somehow to long-term "switching" of neuronal function. Several reports have suggested that lidocaine has second messenger blocking effects, [64-68] however, the concentrations employed in those studies far exceeded the physiologic range used in our study. Of note, a recent report [69] delineates a mechanism whereby the metabotropic glutamate receptor functions as an "on-off" switch through the activation of protein kinases/phosphatases to regulate the inducibility of long-term potentiation in the hippocampus. Such regulation, with durable consequences for the facilitation/inhibition of postsynaptic impulses, may provide one example of a theoretical construct as to how an isolated pharmacologic intervention can exert a persistent effect.
In summary, we have described suppression of allodynia in a rat surgical neuropathy model during acute administration of lidocaine, accompanied by very prolonged continued effects. The site of effect and means of action remain to be elucidated. Further studies are necessary to clarify the mechanisms involved in this potentially very clinically useful effect.
REFERENCES
Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW: The use of oral mexiletine for the treatment of pain after peripheral nerve injury. ANESTHESIOLOGY 76:513-517, 1992.
Chabal C, Russell LC, Burchiel KJ: The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 38:333-338, 1989.
Dejgard A, Petersen P, Kastrup J: Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1:9-11, 1988.
Kastrup J, Angelo HR, Petersen P, Dejgard A, Hilsted J: Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. Br Med J 292:173, 1986.
Kastrup J, Petersen P, Dejgard A, Angelo HR, Hilsted J: Intravenous lidocaine infusion: A new treatment of chronic painful diabetic neuropathy? Pain 28:69-75, 1987.
Marchettini P, Lacerenza M, Marangoni C, Pellegata G, Sotgiu ML, Smirne S: Lidocaine test in neuralgia. Pain 48:377-382, 1992.
Rowbotham MC, Reisnerkeller LA, Fields HL: Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41:1024-1028, 1991.
Bach FW, Jensen TS, Kastrup J, Stigsby B, Dejgard A: The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain 40:29-34, 1990.
Lindstrom P, Lindblom U: The analgesic effect of tocainide in trigeminal neuralgia. Pain 28:45-50, 1987.
Bowsher D: Sensory change in postherpetic neuralgia, Herpes Zoster and Postherpetic Neuralgia. Edited by Watson CPN. Amsterdam, Elsevier, 1993, pp 97-107.
Wahren LK, Torebjork E: Quantitative sensory tests in patients with neuralgia 11 to 25 years after injury. Pain 48:237-244, 1992.
Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363, 1992.
Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17:1031-1036, 1976.
Chaplan SR, Pogrel JW, Yaksh TL: Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 269:1117-1123, 1994.
Bennett PN, Aarons LJ, Bending MR, Steiner JA, Rowland M: Pharmacokinetics of lidocaine and its deethylated metabolite: Dose and time dependency studies in man. J Pharmacokinet Biopharm 10:265-81, 1982.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of allodynia in the rat paw. J Neurosci Methods 53:55-63, 1994.
Draisci G, Kajander KC, Dubner R, Bennett GJ, Iadarola MJ: Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res 560:186-92, 1991.
Galeazza MT, Stucky CL, Seybold VS: Changes in [sup 125 Iodine]hCGRP binding in rat spinal cord in an experimental model of acute, peripheral inflammation. Brain Res 591:198-208, 1992.
Kajander KC, Sahara Y, Iadarola MJ, Bennett GJ: Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 11:719-28, 1990.
Kar S, Rees RG, Quirion R: Altered calcitonin gene-related peptide, substance P and enkephalin immunoreactivities and receptor binding sites in the dorsal spinal cord of the polyarthritic rat. Eur J Neurosci 6:345-54, 1994.
Dixon WJ: Efficient analysis of experimental observations. Ann Rev Pharmacol Toxicol 20:441-462, 1980.
Chen Y, Poeetr JM, Ravenscroft PJ: A quick, sensitive high-performance liquid chromatography assay for monoethyl-glycinexylidide and lignocaine in serum/plasma using solid-phase extraction. Thera Drug Monitor 14:317-321, 1992.
Bjork M, Pettersson KJ, Osterlof G: Capillary gas chromatographic method for the simultaneous determination of local anaesthetics in plasma samples. J Chromatogr 533:229-34, 1990.
Kajander KC, Wakisaka S, Bennett GJ: Spontaneous discharge originates in the dorsal root ganglion at the onset of a painful peripheral neuropathy in the rat. Neurosci Lett 138:225-228, 1992.
Devor M, Govrin-Lippmann R, Angelides K: Sodium + channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 13:1976-1992, 1993.
Devor M, Keller CH, Deerinck TJ, Levinson SR, Ellisman MH: Sodium + channel accumulation on axolemma of afferent endings in nerve end neuromas in Apteronotus. Neurosci Lett 102:149-154, 1989.
Matzner O, Devor M: Sodium + conductance and the threshold for repetitive neuronal firing. Brain Res 597:92-98, 1992.
Na HS, Leem JW, Chung JM: Abnormalities of mechanoreceptors in a rat model of neuropathic pain: Possible involvement in mediating mechanical allodynia. J Neurophysiol 70:522-528, 1993.
Lombard MC, Besson JM: Attempts to gauge the relative importance of pre- and postsynaptic effects of morphine on the transmission of noxious mesages in the dorsal horn of the rat spinal cord. Pain 37:335-345, 1989.
Palecek J, Dougherty PM, Kim SH, Paleckova V, Lekan H, Chung JM, Carlton SM, Willis WD: Responses of spinothalamic tract neurons to mechanical and thermal stimuli in an experimental model of peripheral neuropathy in primates. J Neurophysiol 68:1951-1966, 1992.
Dickenson AH, Sullivan AF: Evidence for involvement of N-methylaspartate receptors in 'wind-up' of class 2 neurones in the dorsal horn of the rat. Brain Res 424:402-406, 1987.
Bach FW, Chaplan SR, Yaksh TL: Studies on the spinal pharmacology of a new model of allodynia. (abstract) Ann Neurol 36:288A, 1994.
Sato J, Perl ER: Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 251:1608-1610, 1991.
Xie YK, Xiao WH, Li HQ: The relationship between new ion channels and ectopic discharges from a region of nerve injury. Sci China B 36:68-74, 1993.
Mao J, Mayer DJ, Hayes RL, Price DD: Spatial patterns of increased spinal cord membrane-bound protein kinase-C and their relation to increases in C-14-2-deoxyglucose metabolic activity in rats with painful peripheral mononeuropathy. J Neurophysiol 70:470-481, 1993.
Mao JR, Price DD, Mayer DJ, Hayes RL: Pain-related increases in spinal cord membrane-bound protein kinase-C following peripheral nerve injury. Brain Res 588:144-149, 1992.
Bennett GJ, Kajander KC, Sahara Y, Iadarola MJ, Sugimoto T: Neurochemical and anatomical changes in the dorsal horn of rats with an experimental painful peripheral neuropathy, Processing of Sensory Information in the Superficial Dorsal Horn of Spinal Cord. Edited by Cervero F, Bennett GJ, Headley P. New York, Plenum, 1989, pp 463-471.
Sugimoto T, Bennett GJ, Kajander KC: Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: Effects of a chronic constriction injury, transection, and strychnine. Pain 42:205-213, 1990.
Yaksh T: Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: Effects of modulatory receptor systems and excitatory amino acid antagonists. Pain 37:111-123, 1989.
Dohi S, Kitahata LM, Toyooka H, Ohtani M, Namiki A, Taub A: An analgesic action of intravenously administered lidocaine on dorsal-horn neurons responding to noxious thermal stimulation. ANESTHESIOLOGY 51:123-126, 1979.
Sotgiu ML, Biella G, Castagna A, Lacerenza M, Marchettini P: Different time-courses of i.v. lidocaine effect on ganglionic and spinal units in neuropathic rats. Neuroreport 5:873-, 1994.
Sotgiu ML, Lacerenza M, Marchettini P: Selective inhibition by systemic lidocaine of noxious evoked activity in rat dorsal horn neurons. Neuroreport 2:425-428, 1991.
Sotgiu ML, Lacerenza M, Marchettini P: Effect of systemic lidocaine on dorsal horn neuron hyperactivity following chronic peripheral nerve injury in rats. Somatosens Mot Res 9:227-233, 1992.
Woolf CJ, Wiesenfeld-Hallin Z: The systemic administration of local anesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. Pain 23:361-374, 1985.
Strichartz GR, Sanchez V, Arthur GR, Chafetz R, Martin D: Fundamental properties of local anesthetics. II. Measured octanol: buffer partition coefficients and pKa values of clinically used drugs. Anesth Analg 71:158-170, 1990.
Usubiaga JE, Moya F, Wikinski JA: Relationship between the passage of local anesthetics across the blood-brain barrier and their effects on the central nervous system. Br J Anaesth 39:943-947, 1967.
Tanelian DL, Maclver MB: Analgesic concentrations of lidocaine suppress tonic A-delta and C-fiber discharges produced by acute injury. ANESTHESIOLOGY 74:934-936, 1991.
Devor M, Wall PD, Catalan N: Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 48:261-268, 1992.
Burney RG, DiFazio CA, Peach MJ, Petrie KA, Silvester MJ: Anti-arrhythmic effects of lidocaine metabolites. Am Heart J 88:765-769, 1974.
Biella G, Sotgiu ML: Central effects of systemic lidocaine mediated by glycine spinal receptors: An iontophoretic study in the rat spinal cord. Brain Res 603:201-206, 1992.
Kim SH, Chung JM: Sympathectomy alleviates mechanical allodynia in an experimental animal model for neuropathy in the rat. Neurosci Lett 134:131-134, 1991.
Kim SH, Na HS, Sheen K, Chung JM: Effects of sympathectomy on a rat model of peripheral neuropathy. Pain 55:85-92, 1993.
Hogan QH, Stadnicka A, Stekiel TA, Bosnjak ZJ, Kampine JP: Effects of epidural and systemic lidocaine on sympathetic activity and mesenteric circulation in rabbits. ANESTHESIOLOGY 79:1250-1260, 1993.
Keenaghan JB, Boyes RN: The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther 180:454-463, 1972.
Backonja M, Gombar KA: Response of central pain syndromes to intravenous lidocaine. J Pain Symptom Manage 7:172-178, 1992.
Juhlin L: Long-standing pain relief of adiposis dolorosa (Dercum's disease) after intravenous infusion of lidocaine. J Am Acad Dermatol 15:383-385, 1986.
Abram SE, Yaksh TL: Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. ANESTHESIOLOGY 80:383-391, 1994.
White MM, Chen LQ, Kleinfield R, Kallen RG, Barchi RL: SkM2, a Sodium + channel cDNA clone from denervated skeletal muscle, encodes a tetrodotoxin-insensitive Sodium + channel. Mol Pharmacol 39:604-608, 1991.
Witzemann V, Barg B, Nishikawa Y, Sakmann B, Numa S: Differential regulation of muscle acetylcholine receptor gamma- and epsilon-subunit mRNAs. FEBS Lett 223:104-12, 1987.
Roy ML, Narahashi T: Differential properties of tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in rat dorsal root ganglion neurons. J Neurosci 12:2104-2111, 1992.
Campbell JN, Raja SN, Meyer RA, Mackinnon SE: Myelinated afferents signal the hyperalgesia associated with nerve injury. Pain 32:89-95, 1988.
Price DP, Bennett GJ, Rafii A: Psychophysical observations on patients with neuropathic pain relieved by a sympathetic block. Pain 36:273-288, 1989.
Shir Y, Seltzer Z: A-fibers mediate mechanical hyperesthesia and allodynia and C-fibers mediate thermal hyperalgesia in a new model of causalgiform pain disorders in rats. Neurosci Lett 115:62-67, 1990.
Kai T, Nishimura J, Kobayashi S, Takahashi S, Yoshitake J, Kanaide H: Effects of lidocaine on intracellular Calcium 2+ and tension in airway smooth muscle. ANESTHESIOLOGY 78:954-965, 1993.
Kanbara T, Tomoda MK, Sato EF, Ueda W, Manabe M: Lidocaine inhibits priming and protein tyrosine phosphorylation of human peripheral neutrophils. Biochem Pharmacol 45:1593-8, 1993.
Onozuka M, Watanabe K, Imai S, Nagasaki S, Yamamoto T: Lidocaine suppresses the sodium current in Euhadra neurons which is mediated by cAMP-dependent protein phosphorylation. Brain Res 628:335-339, 1993.
Spedding M, Berg C: Antagonism of Calcium 2+ induced contractions of Potassium +-depolarized smooth muscle by local anesthetics. Eur J Pharmacol 108:143-150, 1985.
Tomoda MK, Tsuchiya M, Ueda W, Hirakawa M, Utsumi K: Lidocaine inhibits stimulation-coupled responses of neutrophils and protein kinase C activity. Physiol Chem Phys Med NMR 22:199-210, 1990.
Bortolotto ZA, Bashir ZI, Davies CH, Collingridge GL: A molecular switch activated by metabotropic glutamate receptors regulates induction of long-term potentiation. Nature 368:740-743, 1994.
Figure 2. Two groups of rats underwent identical intravenous lidocaine infusion protocols, in which a pseudo-steady-state level was sustained over 40 min. One group, consisting of six neuropathic animals, had repeated paw withdrawal threshold testing. The second group consisted of four normal rats equipped with arterial catheters for blood sampling. Samples were drawn at all time points corresponding to paw testing in the neuropathic group; mean plasma lidocaine concentration overall was 1.34 plus/minus 0.07 micro gram/ml. Significant increases in paw withdrawal thresholds were seen beginning 30 min after attaining targeted plasma lidocaine levels. (P < 0.001, repeated measures analysis of variance with mean squares contrasts). X-axis: time; left y-axis: paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE; right y-axis: plasma lidocaine levels, micro gram/ml plus/minus SE.
Figure 2. Two groups of rats underwent identical intravenous lidocaine infusion protocols, in which a pseudo-steady-state level was sustained over 40 min. One group, consisting of six neuropathic animals, had repeated paw withdrawal threshold testing. The second group consisted of four normal rats equipped with arterial catheters for blood sampling. Samples were drawn at all time points corresponding to paw testing in the neuropathic group; mean plasma lidocaine concentration overall was 1.34 plus/minus 0.07 micro gram/ml. Significant increases in paw withdrawal thresholds were seen beginning 30 min after attaining targeted plasma lidocaine levels. (P < 0.001, repeated measures analysis of variance with mean squares contrasts). X-axis: time; left y-axis: paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE; right y-axis: plasma lidocaine levels, micro gram/ml plus/minus SE.
Figure 2. Two groups of rats underwent identical intravenous lidocaine infusion protocols, in which a pseudo-steady-state level was sustained over 40 min. One group, consisting of six neuropathic animals, had repeated paw withdrawal threshold testing. The second group consisted of four normal rats equipped with arterial catheters for blood sampling. Samples were drawn at all time points corresponding to paw testing in the neuropathic group; mean plasma lidocaine concentration overall was 1.34 plus/minus 0.07 micro gram/ml. Significant increases in paw withdrawal thresholds were seen beginning 30 min after attaining targeted plasma lidocaine levels. (P < 0.001, repeated measures analysis of variance with mean squares contrasts). X-axis: time; left y-axis: paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE; right y-axis: plasma lidocaine levels, micro gram/ml plus/minus SE.
×
Figure 1. After a single intravenous lidocaine infusion to complete allodynia suppression or a maximum of 30 mg/kg over approximately 60 min on day 0, neuropathic rats were followed for 3 weeks (N = 6) and simultaneously compared with rats that received saline infusions of equivalent volume using the same paradigm (N = 5). Blinded assessment revealed a highly significant difference between groups, with sustained allodynia suppression in the lidocaine-treated rats, and an absence of spontaneous neuropathy resolution in the saline controls (P = 0.0002, repeated measures analysis of variance). X-axis, day relative to lidocaine infusion; y-axis, paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE.
Figure 1. After a single intravenous lidocaine infusion to complete allodynia suppression or a maximum of 30 mg/kg over approximately 60 min on day 0, neuropathic rats were followed for 3 weeks (N = 6) and simultaneously compared with rats that received saline infusions of equivalent volume using the same paradigm (N = 5). Blinded assessment revealed a highly significant difference between groups, with sustained allodynia suppression in the lidocaine-treated rats, and an absence of spontaneous neuropathy resolution in the saline controls (P = 0.0002, repeated measures analysis of variance). X-axis, day relative to lidocaine infusion; y-axis, paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE.
Figure 1. After a single intravenous lidocaine infusion to complete allodynia suppression or a maximum of 30 mg/kg over approximately 60 min on day 0, neuropathic rats were followed for 3 weeks (N = 6) and simultaneously compared with rats that received saline infusions of equivalent volume using the same paradigm (N = 5). Blinded assessment revealed a highly significant difference between groups, with sustained allodynia suppression in the lidocaine-treated rats, and an absence of spontaneous neuropathy resolution in the saline controls (P = 0.0002, repeated measures analysis of variance). X-axis, day relative to lidocaine infusion; y-axis, paw withdrawal thresholds expressed as percent of maximum possible effect plus/minus SE.
×
Figure 3. Two groups of neuropathic rats received the same total dose of intravenous lidocaine (15 mg/kg), delivered in one group (A) as a faster infusion achieving a mean plasma lidocaine concentration of 1.2 micro gram/ml (N = 11), and in the other group (B) as a slower infusion achieving a mean concentration of 0.6 micro gram/ml (N = 9). Paw withdrawal thresholds were tested every 10 min, and blood levels were drawn at the achievement of allodynia suppression, or at the end of the infusion. Median paw withdrawal thresholds are shown for pretreatment baseline, immediately post treatment, and posttreatment days 1,5 and 7 (N = 8, group A, and N = 6, group B). Error bars represent interquartile range. Whereas significant threshold increases were achieved after acute infusion in group A (P = 0.0033, Wilcoxon signed-rank test), which persisted at least 7 days (P = 0.0006, Friedman test), threshold changes in group B did not reach significance acutely (P = 0.067, Wilcoxon signed-rank test) and were not significant during follow-up (P = 0.67, Friedman test). X-axis: time points; y-axis: median paw withdrawal thresholds (g).
Figure 3. Two groups of neuropathic rats received the same total dose of intravenous lidocaine (15 mg/kg), delivered in one group (A) as a faster infusion achieving a mean plasma lidocaine concentration of 1.2 micro gram/ml (N = 11), and in the other group (B) as a slower infusion achieving a mean concentration of 0.6 micro gram/ml (N = 9). Paw withdrawal thresholds were tested every 10 min, and blood levels were drawn at the achievement of allodynia suppression, or at the end of the infusion. Median paw withdrawal thresholds are shown for pretreatment baseline, immediately post treatment, and posttreatment days 1,5 and 7 (N = 8, group A, and N = 6, group B). Error bars represent interquartile range. Whereas significant threshold increases were achieved after acute infusion in group A (P = 0.0033, Wilcoxon signed-rank test), which persisted at least 7 days (P = 0.0006, Friedman test), threshold changes in group B did not reach significance acutely (P = 0.067, Wilcoxon signed-rank test) and were not significant during follow-up (P = 0.67, Friedman test). X-axis: time points; y-axis: median paw withdrawal thresholds (g).
Figure 3. Two groups of neuropathic rats received the same total dose of intravenous lidocaine (15 mg/kg), delivered in one group (A) as a faster infusion achieving a mean plasma lidocaine concentration of 1.2 micro gram/ml (N = 11), and in the other group (B) as a slower infusion achieving a mean concentration of 0.6 micro gram/ml (N = 9). Paw withdrawal thresholds were tested every 10 min, and blood levels were drawn at the achievement of allodynia suppression, or at the end of the infusion. Median paw withdrawal thresholds are shown for pretreatment baseline, immediately post treatment, and posttreatment days 1,5 and 7 (N = 8, group A, and N = 6, group B). Error bars represent interquartile range. Whereas significant threshold increases were achieved after acute infusion in group A (P = 0.0033, Wilcoxon signed-rank test), which persisted at least 7 days (P = 0.0006, Friedman test), threshold changes in group B did not reach significance acutely (P = 0.067, Wilcoxon signed-rank test) and were not significant during follow-up (P = 0.67, Friedman test). X-axis: time points; y-axis: median paw withdrawal thresholds (g).
×
Figure 4. (A) Lidocaine 500 micro gram was administered intrathecally to six neuropathic rats (10 micro liter of 5% lidocaine in saline). This dose was chosen to exceed hypothetical cerebrospinal fluid concentrations of lidocaine achieved with intravenous infusion. All rats developed complete, transient lower body flaccidity (effective spinal anesthesia). After resolution of motor weakness, paw withdrawal thresholds were compared to predrug values. The significant albeit small effect at 45 min (P = 0.02, repeated measures analysis of variance with means comparisons contrast tests) was not present at 30 min and was absent by 60 min. (B) Catheters were implanted at the site of nerve ligation with orifices directed centrally (6 rats). After full recovery and documentation of withdrawal thresholds to von Frey hairs, catheters were injected with 50 micro liter of 2% lidocaine (1 mg = approximately 4 mg/kg in a 250 g rat). Transient analgesia to paw pinch and partial paw weakness were seen in all six rats (data not shown), demonstrating satisfactory delivery to the ligation site. By 15 min after treatment, von Frey hair thresholds were again indistinguishable from pretreatment (P = 0.97, repeated measures analysis of variance, means comparisons contrasts). X-axes: time; y-axes: paw withdrawal thresholds expressed as percent of maximum possible effect.
Figure 4. (A) Lidocaine 500 micro gram was administered intrathecally to six neuropathic rats (10 micro liter of 5% lidocaine in saline). This dose was chosen to exceed hypothetical cerebrospinal fluid concentrations of lidocaine achieved with intravenous infusion. All rats developed complete, transient lower body flaccidity (effective spinal anesthesia). After resolution of motor weakness, paw withdrawal thresholds were compared to predrug values. The significant albeit small effect at 45 min (P = 0.02, repeated measures analysis of variance with means comparisons contrast tests) was not present at 30 min and was absent by 60 min. (B) Catheters were implanted at the site of nerve ligation with orifices directed centrally (6 rats). After full recovery and documentation of withdrawal thresholds to von Frey hairs, catheters were injected with 50 micro liter of 2% lidocaine (1 mg = approximately 4 mg/kg in a 250 g rat). Transient analgesia to paw pinch and partial paw weakness were seen in all six rats (data not shown), demonstrating satisfactory delivery to the ligation site. By 15 min after treatment, von Frey hair thresholds were again indistinguishable from pretreatment (P = 0.97, repeated measures analysis of variance, means comparisons contrasts). X-axes: time; y-axes: paw withdrawal thresholds expressed as percent of maximum possible effect.
Figure 4. (A) Lidocaine 500 micro gram was administered intrathecally to six neuropathic rats (10 micro liter of 5% lidocaine in saline). This dose was chosen to exceed hypothetical cerebrospinal fluid concentrations of lidocaine achieved with intravenous infusion. All rats developed complete, transient lower body flaccidity (effective spinal anesthesia). After resolution of motor weakness, paw withdrawal thresholds were compared to predrug values. The significant albeit small effect at 45 min (P = 0.02, repeated measures analysis of variance with means comparisons contrast tests) was not present at 30 min and was absent by 60 min. (B) Catheters were implanted at the site of nerve ligation with orifices directed centrally (6 rats). After full recovery and documentation of withdrawal thresholds to von Frey hairs, catheters were injected with 50 micro liter of 2% lidocaine (1 mg = approximately 4 mg/kg in a 250 g rat). Transient analgesia to paw pinch and partial paw weakness were seen in all six rats (data not shown), demonstrating satisfactory delivery to the ligation site. By 15 min after treatment, von Frey hair thresholds were again indistinguishable from pretreatment (P = 0.97, repeated measures analysis of variance, means comparisons contrasts). X-axes: time; y-axes: paw withdrawal thresholds expressed as percent of maximum possible effect.
×
Figure 5. Intravenous infusion of lidocaine, using a software-driven syringe pump, produced pseudo-steady-state plasma lidocaine levels during which paw withdrawal thresholds were measured. Arterial lidocaine levels drawn greater or equal to 30 min after start of infusion correlated with the degree of suppression of allodynia. There were no signs of toxicity at the levels illustrated. Untransformed data (inset): x-axis = log measured lidocaine concentration, y-axis = percent of maximum possible effect. In the surrounding figure, percent of maximum possible effect has been given logit transformation (y' = log [y/(100 - y)]) for linear depiction of the sigmoid dose-response curve. R = 0.76, P < 0.01, linear regression. X-axis: log measured plasma lidocaine concentration; y-axis, logit transformation of percent of maximum possible effect as above.
Figure 5. Intravenous infusion of lidocaine, using a software-driven syringe pump, produced pseudo-steady-state plasma lidocaine levels during which paw withdrawal thresholds were measured. Arterial lidocaine levels drawn greater or equal to 30 min after start of infusion correlated with the degree of suppression of allodynia. There were no signs of toxicity at the levels illustrated. Untransformed data (inset): x-axis = log measured lidocaine concentration, y-axis = percent of maximum possible effect. In the surrounding figure, percent of maximum possible effect has been given logit transformation (y' = log [y/(100 - y)]) for linear depiction of the sigmoid dose-response curve. R = 0.76, P < 0.01, linear regression. X-axis: log measured plasma lidocaine concentration; y-axis, logit transformation of percent of maximum possible effect as above.
Figure 5. Intravenous infusion of lidocaine, using a software-driven syringe pump, produced pseudo-steady-state plasma lidocaine levels during which paw withdrawal thresholds were measured. Arterial lidocaine levels drawn greater or equal to 30 min after start of infusion correlated with the degree of suppression of allodynia. There were no signs of toxicity at the levels illustrated. Untransformed data (inset): x-axis = log measured lidocaine concentration, y-axis = percent of maximum possible effect. In the surrounding figure, percent of maximum possible effect has been given logit transformation (y' = log [y/(100 - y)]) for linear depiction of the sigmoid dose-response curve. R = 0.76, P < 0.01, linear regression. X-axis: log measured plasma lidocaine concentration; y-axis, logit transformation of percent of maximum possible effect as above.
×